AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06084637 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Intra-articular injection of autologous platelet-rich plasma
Description: A preparation of autologous platelet-rich plasma (5mL) will be injected intra-articularly.
Study NCT06084637 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Intra-articular injection of autologous microfat and platelet-rich plasma
Description: A preparation of autologous platelet-rich plasma (5mL) and autologous microfat (5mL) will be injected intra-articularly.
Study NCT05816343 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Orlistat
Description: Orlistat is an inhibitor of gastric and pancreatic lipases and can reduce dietary fat absorption by 30%. Orlistat at a dose of 2 capsules (each containing 60 mg of active drug) three times a day with each meal (a total dose of 360 mg daily).
Study NCT05816343 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo at a dose of 2 capsules (each containing 60 mg placebo) three times a day with each meal (a total dose of 360 mg daily).
Study NCT05683405 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non-surgical treatment of peri-implantitis with mechanical debridement
Description: Non-surgical treatment of peri-implantitis with mechanical debridement .
Study NCT05683405 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non-surgical treatment of peri-implantitis with air polishing
Description: Non-surgical treatment of peri-implantitis with air polishing
Study NCT04784052 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JSP191
Description: Participants will receive a single IV dose at start of conditioning
Study NCT04784052 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CliniMACS Prodigy System
Description: The device used to remove the αβ+T cells from donor stem cell transplant before being given to the recipient
Study NCT04784052 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Depleted Stem Cell Transplant
Description: TCRαβ+ T-cell/CD19+ B-cell depleted hematopoietic cells will be administered by IV after completion of conditioning regimen.
Study NCT04784052 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rabbit Anti-Thymoglobulin (rATG)
Description: 3 consecutive daily doses of rATG will be given by IV during conditioning
Study NCT04784052 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 4 consecutive daily doses of cyclophosphamid will be given by IV during conditioning
Study NCT04784052 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 4 consecutive daily doses of fludarabine will be given by IV during conditioning
Study NCT04784052 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 1 dose of rituximab will be given at the end of conditioning
Study NCT05171400 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Palatal Wound
Description: With the goal to harvest the free gingival graft (FGG), an 8mm diameter scalpel will be used to ensure standardized wounds. Thereafter, a 2-mm thick FGG will be removed. The wound area will receive 4.0 silk sutures.
Study NCT05171400 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Palatal Wound
Description: With the goal to harvest the free gingival graft (FGG), an 8mm diameter scalpel will be used to ensure standardized wounds. Thereafter, a 2-mm thick FGG will be removed. The wound area will receive 4.0 silk sutures.
Study NCT05171400 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Palatal Wound treated with Silk Fibroin Film
Description: With the goal to harvest the free gingival graft (FGG), an 8mm diameter scalpel will be used to ensure standardized wounds. Thereafter, a 2-mm thick FGG will be removed. The wound area will receive a silk fibroin film and 4.0 silk sutures.
Study NCT05171400 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Palatal Wound treated with Insulin-loaded Silk Fibroin Film
Description: With the goal to harvest the free gingival graft (FGG), an 8mm diameter scalpel will be used to ensure standardized wounds. Thereafter, a 2-mm thick FGG will be removed. The wound area will receive a silk fibroin film loaded with insulin and 4.0 silk sutures.
Study NCT06791343 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: AI-Based Diagnostic and Prognostic Model
Description: This intervention involves an AI system that integrates multimodal data, including maternal health records, laboratory test results, and imaging data, to predict the risk of maternal and neonatal diseases. The system uses deep learning algorithms to provide real-time, accurate predictions, enabling early identification of health complications. By analyzing historical health data, the model aims to predict potential risks for both mothers and infants, improving early intervention and outcomes.
Study NCT06302946 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: neuromuscular stimulation ,mindfulness breathing and traditional physiotherapy program
Description: Receive neuromuscular stimulation, mindfulness breathing, and a traditional physiotherapy program. The experimental group participants will receive neuromuscular electrical stimulation with Mindful breathing additionally traditional physiotherapy program
Study NCT06302946 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: traditional physiotherapy program
Description: participants in the control group perceived the traditional physiotherapy program
Study NCT06789783 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lithium Carbonate Capsule
Description: 10mg/Kg twice a day, 150mg or 300mg Lithium Carbonate
Study NCT05980169 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SensoniQ Treatment Station
Description: The SensoniQ® Treatment Station is a chemotherapy chair with multiple transducers that release low- frequency sound waves to different points on the body in a preset frequency, distribution and time during a chemotherapy infusion.
Study NCT05084430 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M032
Description: Starting at week four, patients will undergo treatment on the same day, and every three weeks thereafter, with intravenous infusion of 200mg of Pembrolizumab . A total of 3 combined doses of Pembrolizumab and M032 will be given.
Study NCT05084430 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Starting at week four, patients will undergo treatment on the same day, and every three weeks thereafter, with intravenous infusion of 200mg of Pembrolizumab . A total of 3 combined doses of Pembrolizumab and M032 will be given.
Study NCT06551324 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06821497
Description: 875 mg BID (2 times a day)
Study NCT06551324 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: 75 mg/m2 IV (every 21 days)
Study NCT06551324 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: 160 mg QD
Study NCT06551324 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enzalutamide
Description: 160 mg QD
Study NCT06204744 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home-based GRASP program
Description: The home-based Graded Repetitive Arm Supplementary Program (GRASP) is designed to improve the upper extremity function for people with stroke, including exercises for stretching, coordination, arm and hand strengthening, and fine motor skills.
Study NCT06204744 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional occupational therapy home program
Description: The conventional OT home program will be prescribed by the occupational therapists, customizing stroke rehabilitation exercises to individual patient goals, with a primary focus on improving upper extremity function.
Study NCT05306509 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: NiCE
Description: Participants will receive an initial conversation led by a trained senior nurse within eight weeks after initial oncologic diagnosis or relapse/recurrent disease diagnosis, with an introduction to the intervention and learning about the goals, values, hopes, and fears of each patient and family. The PPC team will then follow each patient by ongoing regular conversations (related to the child and family's conditions) led by the same nurse, every 4 weeks for six months, when symptom assessment and management, goal-directed supportive care, team collaboration, and care coordination will be delivered according to the family's needs. Increased PPC involvement, end-of-life care and bereavement care will be involved when necessary. If a participant feels any discomfort or distress during the intervention, a break will be taken until they feel better. If not, the central contact person will come and discussion about the participant's feeling and wiliness to continue the intervention.
Study NCT05306509 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Routine PPC
Description: Participants will be scheduled to meet with the PPC team only when participants themselves, their families, or the attending oncologist requested an appointment.
Study NCT05659030 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education
Description: In order to develop the training material, first of all, a literature review will be made and a training booklet will be prepared. The training booklet will be submitted to expert opinion and a pilot application will be made by giving its final form. The training content is based on Pender's Health Promotion Model, which consists of 3 components.
Study NCT05422703 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Kinesio tape
Description: Skin-colored Kinesiology Tape (ARES tape,5 cm×5 m) is waterproof tape is made of 100% cotton,applied in the shape of a fan strip, waterproof. The width is 5 cm and thickness of 0.5 mm (5 cm×5 m ).This tape is sticking with a small stretch (about 15%).
Study NCT05422703 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Gauze pack
Description: Place gauze pack over surgical site for one hour after surgery.
Study NCT05422703 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gauze pack
Description: Place gauze pack over surgical site for one hour after surgery.
Study NCT05422703 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: ice pack
Description: Ice packs will be applied for 6 hours after surgery in all patients
Study NCT05422703 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ice pack
Description: Ice packs will be applied for 6 hours after surgery in all patients
Study NCT05422703 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Manual therapy
Description: passive and active range of motion, stretching exercises, resistive mouth exercises, mobilization exercises and coordination exercices.
Study NCT05422703 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Analgesic
Description: NSAIDs like ibuprofen (600-800 mg) or declophenac sodium (50-150 mg) 3 times a day
Study NCT05422703 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Analgesic
Description: NSAIDs like ibuprofen (600-800 mg) or declophenac sodium (50-150 mg) 3 times a day
Study NCT05422703 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Proteolytic enzymes
Description: 1-2 ampoules daily IM box of 3 ampoules of 5 mg crystallized and lyophilized chymotrypsin (450 E. A. Units) + 3 ampoules of 3 ml apyrogenic saline for one week.
Study NCT05422703 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Proteolytic enzymes
Description: 1-2 ampoules daily IM box of 3 ampoules of 5 mg crystallized and lyophilized chymotrypsin (450 E. A. Units) + 3 ampoules of 3 ml apyrogenic saline for one week.
Study NCT05422703 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Mouth wash
Description: use 0.12% chlorhexidine or povidone iodine mouthwash daily
Study NCT05422703 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mouth wash
Description: use 0.12% chlorhexidine or povidone iodine mouthwash daily
Study NCT05422703 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Soft cold diet
Description: For the day of surgery
Study NCT06475352 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FOLFOX regimen
Description: Oxaliplatin will be administered at a fixed dose of 85 mg/m² by 2h intravenous (IV) infusion concurrently with folinic acid 400 mg/m² (or 200 mg/m² if L-folinic acid) as a 2 h IV infusion on day 1 of each 14-day cycle followed by 5-fluorouracil (5-FU) 400 mg/m² IV bolus on day 1, then continuous IV infusion of 1,200 mg/m² /day × 2 days (total 2400 mg/m² for 46-48 hours)
Study NCT06019637 — intervention group
Intervention type: OTHER
Intervention: Onasemnogene Abeparvovec
Description: Retrospective and prospective observational study. There is no treatment allocation.
Study NCT05267730 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Conectar Jugando Game Program
Description: Modern Board and Card Games as Cognitive Training in Rural Elementary Classrooms
Study NCT04711902 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AIN457
Description: Secukinumab 150 mg was supplied in 1.0 mL prefilled syringe, administered via subcutaneous injection
Study NCT04711902 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AIN457
Description: Secukinumab 150 mg was supplied in 1.0 mL prefilled syringe, administered via subcutaneous injection
Study NCT04711902 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Secukinumab Placebo
Description: Secukinumab placebo was supplied in 1.0 mL prefilled syringe, administered via subcutaneous injection
Study NCT04711902 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Secukinumab Placebo
Description: Secukinumab placebo was supplied in 1.0 mL prefilled syringe, administered via subcutaneous injection
Study NCT05807854 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Arthroscopy
Description: The surgeon reattaches the torn tendon to the bone with anchors and sutures.
Study NCT05807854 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Reverse Shoulder Arthroplasty
Description: It consists in replacing the shoulder joint with a total shoulder prosthesis (reverse design).
Study NCT05422703 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Soft cold diet
Description: For the day of surgery
Study NCT06475352 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOX regimen
Description: Oxaliplatin will be administered at a fixed dose of 85 mg/m² by 2h intravenous (IV) infusion concurrently with folinic acid 400 mg/m² (or 200 mg/m² if L-folinic acid) as a 2 h IV infusion on day 1 of each 14-day cycle followed by 5-fluorouracil (5-FU) 400 mg/m² IV bolus on day 1, then continuous IV infusion of 1,200 mg/m² /day × 2 days (total 2400 mg/m² for 46-48 hours)
Study NCT06475352 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CAPOX regimen
Description: Oxaliplatin will be administered at a fixed dose of 130 mg/m² by 2h IV infusion on day 1 of each 21-day cycle followed by capecitabine (1000 mg/m²) twice a day (BID) during 2 weeks, every 3 weeks
Study NCT06475352 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAPOX regimen
Description: Oxaliplatin will be administered at a fixed dose of 130 mg/m² by 2h IV infusion on day 1 of each 21-day cycle followed by capecitabine (1000 mg/m²) twice a day (BID) during 2 weeks, every 3 weeks
Study NCT06168461 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: 162mg aspirin capsule
Study NCT06168461 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo capsule
Study NCT06788522 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Suvorexant
Description: Suvorexant pills (10-20 mg)
Study NCT06788522 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo pills
Study NCT06791252 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: genital hygiene education
Description: The pregnant women in the experimental group were given genital hygiene training individually and in their own homes by the researcher. During the training, the privacy of the client was observed and the researcher and the pregnant women were left alone in the room where the training would be given. Care was taken to ensure that the environment was quiet and calm while the training was given. It was preferred that the pregnant women be in the most comfortable position during the training.~The training was completed by explaining each topic in the training booklet in an average of 20-25 minutes.~Genital hygiene training content:~Session 1 (Day 1): After the introduction phase, information was given about the method to be followed in the study to the pregnant women who agreed to participate in the study. Then, the Minimum Informed Consent Form was given to these women, and the pregnant women who approved the form after reading it were included in the study. Pre-test data were collecte
Study NCT06155292 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Standard Communication Email
Description: This is a standard quarterly email communication without personalized performance metrics.
Study NCT06155292 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized Report Card Email
Description: This personalized information about physician performance replaces the standard communication email to provide personalized feedback to physicians.
Study NCT06155292 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Bottom-Up Framing
Description: The bottom-up framing is added onto the personalized communication email to provide insight on how the PCCE program was informed by physician feedback.~The bottom-up framing is added onto the survey communication to provide insight on how the PCCE program was informed by physician feedback.
Study NCT06787183 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Short course radiotherapy
Description: CTV 25Gy/5Fx.
Study NCT06787183 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 1000mg/m2, d1-14，bid, q3w, 2 cycles.
Study NCT06787183 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 130mg/m2, d1, q3w, 2 cycles
Study NCT06787183 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QL1706
Description: 5.0 mg/kg, q3w
Study NCT06789653 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: p16INK4a mRNA level assessment
Description: Blood samples will be collected at two time points, plasma samples will be aliquoted, and T cells will be separated and expression of p16INK4a mRNA in peripheral blood T-lymphocytes will be determined
Study NCT06789653 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: organ-specific protein signatures assessment
Description: Blood samples will be collected at two time points, plasma samples will be aliquoted, and organ-specific protein signatures assessment will be determined.
Study NCT06789679 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine, albumin-bound paclitaxel, S-1
Description: Albumin-bound paclitaxel：125mg/m2，ivgtt，D1，q2w Gem：1000mg/m2，ivgtt，D1，q2w S-1：40-60mg Bid，PO，d1-7，q2w
Study NCT06789679 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine, albumin-bound paclitaxel
Description: Albumin-bound paclitaxel：125mg/m2，ivgtt，D1，D8，q3w Gem：1000mg/m2，ivgtt，D1，D8，q3w
Study NCT06788821 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Description of the trend of major thyroid ultrasound biometric parameters
Description: Use of prenatal ultrasonography for diagnosis and prognostic guidance in suspected fetal thyroid changes.
Study NCT05761899 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Gene-Corrected Macrophages administered by bronchoscopic instillation
Description: This study will evaluate administration of autologous bone marrow CD34+ cell-derived, CSF2RA lentiviral vector-transduced macrophages (CSF2RA gene-corrected macrophages) by bronchoscopic instillation into individual lung segments on three occasions at 2-month intervals in patients with hPAP. The target (maximum) number of cells to be administered is 778 million gene-corrected macrophages per 70 kg patient, which is equal to 11.1 million cells/kg of ideal body weight.
Study NCT05374512 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dato-DXd
Description: Experimental drug. Provided in 100mg vials. IV infusion.
Study NCT05374512 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: IV Infusion. Active comparator
Study NCT05374512 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nab-paclitaxel
Description: IV infusion. Active comparator
Study NCT05374512 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: IV infusion. Active comparator
Study NCT05374512 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: Tablet. Oral route of administration. Active comparator
Study NCT05374512 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eribulin mesylate
Description: IV infusion. Active comparator
Study NCT04617314 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RC108
Description: RC108 for injection is a novel antibody-drug conjugate, with a c-Met-targeting antibody and a microtube inhibitor.
Study NCT05281510 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vesatolimod
Description: Administered orally
Study NCT05281510 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC07523LS
Description: Administered intravenously